HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Therapy-related acute promyelocytic leukemia with t(15;17) (q22;q12) following chemotherapy with drugs targeting DNA topoisomerase II. A report of two cases and a review of the literature.

AbstractBACKGROUND:
The development of therapy-related acute myeloid leukemia (t-AML) with balanced translocations to chromosome bands 11q23 and 21q22 has recently been significantly related to previous treatment with several cytostatic drugs poisoning DNA topoisomerase II. A similar association was suspected for other balanced chromosomal aberrations such as the t(15;17) characteristic of acute promyelocytic leukemia (APL).
PATIENTS AND METHODS:
Two cases of acute promyelocytic leukemia were observed following treatment for seminoma with etoposide, cisplatin, and bleomycin and treatment for breast cancer with 4-epi-doxorubicin and subsequent cyclophosphamide, methotrexate, and 5-fluorouracil followed by radiotherapy. Both cases presented a t(15;17) (q22;q12) and were examined for the characteristic chimeric rearrangement of the RAR alpha and PML genes observed in acute promyelocytic leukemia de-novo.
RESULTS:
In both cases the characteristic chimeric rearrangement was demonstrated. Case no. 2 in addition to the t(15;17) showed an inversion of the long arm of a chromosome no. 5 and a del(7)(q22) in all abnormal mitoses studied. Despite these findings the patient obtained a complete morphological and cytogenetic remission of the leukemia following treatment with all-trans-retinoic acid.
CONCLUSIONS:
Based on these two cases and a review of the literature it is concluded that the development of t-APL with the balanced translocation t(15;17) is related to previous treatment with cytostatic drugs targeting DNA topoisomerase II and that additional abnormalities of the long arms of chromosomes no. 5 and no. 7 do not interfere with the induction of remission with all-trans-retinoic acid.
AuthorsL Hoffmann, P Möller, J Pedersen-Bjergaard, A Waage, M Pedersen, F R Hirsch
JournalAnnals of oncology : official journal of the European Society for Medical Oncology / ESMO (Ann Oncol) Vol. 6 Issue 8 Pg. 781-8 (Oct 1995) ISSN: 0923-7534 [Print] NETHERLANDS
PMID8589015 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Topoisomerase II Inhibitors
Topics
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects)
  • Base Sequence
  • Breast Neoplasms (drug therapy)
  • Female
  • Humans
  • Leukemia, Promyelocytic, Acute (enzymology, etiology, genetics)
  • Male
  • Middle Aged
  • Molecular Sequence Data
  • Neoplasms, Second Primary (enzymology, etiology, genetics)
  • Seminoma (drug therapy)
  • Testicular Neoplasms (drug therapy)
  • Topoisomerase II Inhibitors
  • Translocation, Genetic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $490.00 USD